Compare PDEX & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDEX | CRBP |
|---|---|---|
| Founded | 1978 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.2M | 184.4M |
| IPO Year | 1995 | 2014 |
| Metric | PDEX | CRBP |
|---|---|---|
| Price | $65.75 | $7.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $56.00 | $45.50 |
| AVG Volume (30 Days) | 23.7K | ★ 692.8K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 345.00 | N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | ★ $66,593,000.00 | $4,822,272.00 |
| Revenue This Year | $7.22 | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | $19.94 | ★ N/A |
| Revenue Growth | 23.68 | ★ 97.62 |
| 52 Week Low | $23.52 | $6.73 |
| 52 Week High | $68.99 | $20.56 |
| Indicator | PDEX | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 65.82 | 37.53 |
| Support Level | $37.43 | N/A |
| Resistance Level | N/A | $8.87 |
| Average True Range (ATR) | 2.80 | 0.81 |
| MACD | -0.03 | -0.22 |
| Stochastic Oscillator | 91.17 | 6.08 |
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.